2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10638A
    TAT-CN21 (scrambled) 99.71%
    TAT-CN21 (scrambled) is a nonsense sequence control peptide fused with the TAT cell-penetrating sequence. It exerts no inhibitory effect on CaMKII activity and serves as a negative control for TatCN21 (HY-P10638).
    TAT-CN21 (scrambled)
  • HY-P10948A
    CS-VIP 8 hydrochloride
    CS-VIP 8 hydrochloride is a selective allosteric WDR5 protein inhibitor (Ki= 0.008 μM). CS-VIP 8 hydrochloride induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 hydrochloride is promising for research of hematological diseases such as leukemia.
    CS-VIP 8 hydrochloride
  • HY-P11775A
    Peptide HRH acetate
    Peptide HRH acetate is a polypeptide that specifically binds to VEGF receptors. Peptide HRH acetate inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH acetate inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH acetate can be used in anti-angiogenesis related studies.
    Peptide HRH acetate
  • HY-P991065
    Ichorcumab 2589583-20-8
    Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Ichorcumab
  • HY-P991169
    Zemocimig 2955620-21-8 98%
    Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
    Zemocimig
  • HY-W011082
    NLRP3-IN-2 16673-34-0 98.00%
    NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism.
    NLRP3-IN-2
  • HY-W091734
    Methyl 4-iodo-L-phenylalaninate hydrochloride 158686-46-5
    Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease.
    Methyl 4-iodo-L-phenylalaninate hydrochloride
  • HY-W127841
    Citric acid-2,4-13C2 121633-50-9 98.00%
    Citric acid-2,4-13C2 is the 13C-labeled Citric acid (HY-N1428). Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid is also an acidulant, emulsifier, sequestrant and buffering agent widely used across many industries.
    Citric acid-2,4-13C2
  • HY-W517264
    Carazolol hydrochloride 51997-43-4 99.90%
    Carazolol (BM 51052) hydrochloride is a highly potent antagonist of β1/β2 adrenoceptor. Carazolol hydrochloride is also a potent, selective β3-adrenoceptor agonist. Carazolol hydrochloride can be used in the research of hypertension.
    Carazolol hydrochloride
  • HY-W674245
    10-Hydroxyhexadecanoic acid 23048-75-1 98.91%
    10-Hydroxyhexadecanoic acid is a hydroxy fatty acid found in Camembert cheese. 10-Hydroxyhexadecanoic acid can promote cholesterol efflux from ABCA1 and ABCG1, preventing the accumulation of excess cholesterol in cells. 10-Hydroxyhexadecanoic acid can be used in anti-atherosclerosis research.
    10-Hydroxyhexadecanoic acid
  • HY-W704079
    1-Stearoyl-sn-glycerol 22610-61-3 98.66%
    1-Stearoyl-sn-glycerol is (MG(18:0/0:0/0:0); L-(+)-1-Monostearin; 1-Octadecanoyl-sn-glycerol) is a monoglyceride and also a metabolite found in plasma, which can be used in metabolomic analysis of plasma for coronary artery lesions (CAL).
    1-Stearoyl-sn-glycerol
  • HY-W753672
    2'-O-Methyladenosine-d3 1195030-24-0
    2'-O-Methyl Adenosine-d3 is deuterium labeled 2'-O-Methyl Adenosine. 2'-O-Methyl Adenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyl Adenosine exhibits unique hypotensive activities .
    2'-O-Methyladenosine-d3
  • HY-W996116
    AZM198 1933460-23-1 98.40%
    AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC50=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis.
    AZM198
  • HY-107372S2
    Uridine triphosphate-13C9 dilithium 99.33%
    Uridine triphosphate-13C9 (UTP-13C9 dilithium; Uridine 5'-triphosphate-13C9) dilithium is 13C-labeled Uridine triphosphate (HY-107372). Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.
    Uridine triphosphate-13C9 dilithium
  • HY-W011641R
    (±)-Naringenin (Standard) 67604-48-2 98.82%
    (±)-Naringenin (Standard) is the analytical standard of (±)-Naringenin. This product is intended for research and analytical applications. (±)-Naringenin is a naturally-occurring flavonoid. (±)-Naringenin displays vasorelaxant effect on endothelium-denuded vessels via the activation of BKCa channels in myocytes.
    (±)-Naringenin (Standard)
  • HY-W012982S
    3-Amino-2-oxazolidinone-d4 1188331-23-8 99.90%
    3-Amino-2-oxazolidinone-d4 (AOZ-d4) is a deuterium labeled 3-Amino-2-oxazolidinone (HY-W012982). 3-Amino-2-oxazolidinone (AOZ) is the metabolite of Furazolidone (HY-B1336). 3-Amino-2-oxazolidinone is always be detected as a indicator of furazolidone residues in vivo. 3-Amino-2-oxazolidinone is orally active.
    3-Amino-2-oxazolidinone-d4
  • HY-W013093R
    Uridine triphosphate trisodium salt (Standard) 19817-92-6
    Uridine triphosphate (trisodium salt) (Standard) is the analytical standard of Uridine triphosphate (trisodium salt). This product is intended for research and analytical applications. Uridine triphosphate (UTP) trisodium salt is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate trisodium salt activates membrane-bound P2Y2 receptors.
    Uridine triphosphate trisodium salt (Standard)
  • HY-W013989R
    1,3-Dicyclohexylurea (Standard) 2387-23-7 99.82%
    1,3-Dicyclohexylurea (Standard) is the analytical standard of 1,3-Dicyclohexylurea. This product is intended for research and analytical applications. 1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats.
    1,3-Dicyclohexylurea (Standard)
  • HY-W017007SA
    3-Methyl-L-histidine-d3 hydrochloride 99.67%
    3-Methyl-L-histidine-d3 hydrochloride is the deuterium labeled 3-Methyl-L-histidine hydrochloride. 3-Methyl-L-histidine hydrochloride is an endogenous amino acid that can be found in actin and myosin.
    3-Methyl-L-histidine-d3 hydrochloride
  • HY-14895
    Fabomotizole 173352-21-1 99.96%
    Fabomotizole (CM346) is an insecticide with anxiolytic, antianxiety, and neuroprotective activities and a substrate of p-glycoprotein. Fabomotizole inhibits the ST-segment depression induced by isoproterenol in a rat model of acute subendocardial ischemia. Fabomotizole also inhibits Giardia lamblia and has the potential to inhibit giardiasis. Fabomotizole also targets Sigma1R, NRH:quinone reductase 2 (NQO2), and MAO-A to exert anxiolytic effects.
    Fabomotizole
Cat. No. Product Name / Synonyms Application Reactivity